Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8017533 | 0.87 | HTR2C (0.47) | HTR2CSLC6A4MEN1CRHBPKMT2A | |
| SCHEMBL1403561 | 0.87 | HTR2C (0.40) | HTR2CSLC6A4FOLH1MEN1CRHBP | |
| SCHEMBL22657817 | 0.87 | SLC6A4 (0.44) | HTR2CSLC6A4MEN1CRHBPKMT2A | |
| SCHEMBL29430383 | 0.87 | SLC6A4 (0.44) | HTR2CSLC6A4MEN1CRHBPKMT2A | |
| SCHEMBL3111523 | 0.85 | CYP2C9 (0.41) | HTR2CSLC6A4MEN1CRHBPKMT2A | |
| SCHEMBL1424499 | 0.83 | HTR2C (0.38) | HTR2CSLC6A4MEN1CRHBPKMT2A | |
| SCHEMBL29229835 | 0.82 | SLC6A4 (0.41) | HTR2CSLC6A4MEN1CRHBPKMT2A | |
| SCHEMBL11470297 | 0.82 | HTR2C (0.45) | HTR2CSLC6A4MEN1CRHBPKMT2A | |
| SCHEMBL31126930 | 0.82 | TSHR (0.46) | SLC6A4FOLH1MEN1CRHBPKMT2A | |
| SCHEMBL29430479 | 0.82 | HTR2C (0.45) | HTR2CSLC6A4MEN1CRHBPKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | TERREMOTO BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4653017-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Tyligand Bioscience (Shanghai) Limited (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2025081045-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20240398980-A1 | NUCLEIC ACID-CONJUGATED POLYMERIC NANOPARTICLES AND METHODS OF USE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2024-12-05 | — | — | US | disclosed |
| CN-118873678-A | Antibody-conjugated drugs and uses thereof | 泰励生物科技（上海）有限公司 | 2024-11-01 | — | — | CN | disclosed |
| WO-2024153127-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 泰励生物科技（上海）有限公司 | 2024-07-25 | — | — | WO | disclosed |
| EP-4398942-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | Orum Therapeutics Inc. (KR) | 2024-07-17 | — | — | EP | disclosed |
| CN-118201642-A | Linker for antibody drug conjugates | 奥隆制药 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023037268-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | ORUM THERAPEUTICS, INC. (KR) | 2023-03-16 | — | — | WO | disclosed |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| EP-3965891-A1 | ANTIBODY DRUG CONJUGATES | Takeda Pharmaceutical Company Limited (JP) | 2022-03-16 | — | — | EP | disclosed |
| CN-114173824-A | Antibody drug conjugates | 武田药品工业株式会社 | 2022-03-11 | — | — | CN | disclosed |
| WO-2020229982-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020229982-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398980-A1 | NUCLEIC ACID-CONJUGATED POLYMERIC NANOPARTICLES AND METHODS OF USE | POLN, POLRMT, POLI | HTR2C 4725/4885SLC6A4 2631/4885FOLH1 1261/4885 |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | AKT1, AKT2, AKT3 | HTR2C 1703/4885SLC6A4 3524/4885FOLH1 4154/4885 |
| US-20220409734-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | HTR2C 2901/4885SLC6A4 2287/4885FOLH1 948/4885 |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT2, AKT3 | HTR2C 3549/4885SLC6A4 4185/4885FOLH1 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.